https://www.yiliao.com/index.php?action=history&feed=atom&title=MammaPrint
MammaPrint - 版本历史
2026-04-18T06:57:36Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=MammaPrint&diff=316136&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-29T00:37:40Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>MammaPrint</strong>（70基因检测）是全球首个获得美国 FDA 批准用于早期乳腺癌复发风险评估的体外诊断检测（IVDMIA）。该检测通过微阵列或二代测序技术分析肿瘤组织中 <strong>70 个特定基因</strong>的表达谱，将患者明确地划分为<strong>“低复发风险”</strong>或<strong>“高复发风险”</strong>两类（二元结果）。其核心临床价值在于：帮助那些临床评估为“高危”（如肿瘤较大、淋巴结阳性）但基因组学显示为“低危”的患者，安全地<strong>豁免辅助化疗</strong>。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">MammaPrint</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">70-Gene Signature (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">原理：基于 70 个基因的表达热图</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">检测参数</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">适用人群</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">I-II 期乳腺癌 (LN 0-3)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心结果</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>低危</strong> vs <strong>高危</strong> (Binary)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">检测技术</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">微阵列 (Microarray) / NGS</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">预测重点</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;"><strong>远处转移风险</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">新分类</th><br />
<td style="padding: 6px 12px; color: #16a34a;">极低危 (Ultra Low)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">基因筛选：无偏见的全局搜索</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
与 21 基因检测基于已知功能（如增殖、激素受体）挑选候选基因不同，MammaPrint 采取了<strong>无偏见（Unbiased）</strong>的全基因组筛选策略：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>开发背景：</strong> 研究人员分析了未接受辅助治疗的乳腺癌患者的全基因组表达，找出了与 5 年内发生远处转移最显著相关的 70 个基因。</li><br />
<li style="margin-bottom: 12px;"><strong>基因功能：</strong> 这 70 个基因涵盖了肿瘤发生发展的<strong>七大标志性过程</strong>（Hallmarks of Cancer），包括细胞增殖、侵袭、转移、血管生成、细胞生存等，能够更全面地反映肿瘤的生物学行为。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">MINDACT 研究：化疗豁免的基石</h2><br />
<br />
<div style="background-color: #fff7ed; border-left: 5px solid #ea580c; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<p style="margin: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
<strong>MINDACT</strong> 是一项包含 6693 名患者的大型前瞻性 III 期随机试验。该研究的核心目的是解决<strong>“临床风险”</strong>与<strong>“基因组风险”</strong>不一致时的治疗决策难题。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">风险评估组合</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 40%;">治疗推荐与结果</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">5年无远处转移率 (DMFS)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">临床低危 + 基因低危</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>无需化疗</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">> 97%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; background-color: #eff6ff; color: #1e40af;">临床高危 + 基因低危<br>(矛盾组)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;"><strong>豁免化疗</strong><br>化疗获益极微 (约 1.5%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;"><strong>95.1%</strong> (与化疗组无统计学差异)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">临床高危 + 基因高危</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>必须化疗</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">化疗获益显著</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">巅峰对决：MammaPrint vs 21基因检测</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">如何选择？</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
1. <strong>结果形式：</strong> MammaPrint 给出的是“非黑即白”的二元结果，决策更直接；21基因检测给出的是 0-100 的连续评分，存在“中间地带”。<br />
<br>2. <strong>临床证据：</strong> 21基因检测在预测<strong>化疗获益</strong>（预测性）方面证据更强；MammaPrint 在预测<strong>高危人群能否减法治疗</strong>（预后性）方面证据确凿，尤其是对于淋巴结阳性（1-3枚）的患者。<br />
<br>3. <strong>极低危人群：</strong> MammaPrint 新增的“极低危”（Ultra Low）分类，提示这部分患者甚至可能考虑减免内分泌治疗的时间。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Cardoso F, et al. (2016).</strong> <em>70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：MINDACT 研究的主要发表文献，证实了约 46% 的临床高危患者属于基因低危，可以安全豁免化疗。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Piccart M, et al. (2021).</strong> <em>70-gene signature as an aid to treatment decisions in early-stage breast cancer: updated results of the phase 3 MINDACT trial with an exploratory analysis by age.</em> <strong>[[The Lancet Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：MINDACT 研究的长期随访结果，进一步确认了淋巴结阳性绝经后妇女豁免化疗的安全性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>van 't Veer LJ, et al. (2002).</strong> <em>Gene expression profiling predicts clinical outcome of breast cancer.</em> <strong>[[Nature]]</strong>. <br><br />
<span style="color: #475569;">[点评]：MammaPrint 的起源论文，首次利用微阵列技术定义了预测乳腺癌预后的 70 基因信号。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
乳腺癌精准诊疗 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心竞品</td><br />
<td style="padding: 10px 15px; color: #334155;">[[21基因检测]] (Oncotype DX) • [[EndoPredict]] • [[Prosigna]] (PAM50)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关键研究</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MINDACT]] (MammaPrint) • [[TAILORx]] (Oncotype) • [[RxPONDER]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">应用价值</td><br />
<td style="padding: 10px 15px; color: #334155;">[[降阶梯治疗]] • [[豁免化疗]] • [[极低危]] (Ultra Low)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020